Screening of anti-endotoxin traditional Chinese medicine by target of Lipid A

Abstract

Abstract: AIM: To screen anti-endotoxin traditional Chinese medicine(TCM) from anti-inflammation TCM by Biosensor,and to furtherstudy anti-endotoxin effective materials of TCM.METHODS: Non-derivatised cuvette immobilised Lipid A was used to track the bonding be-tween the Lipid A and aqueous extracts and alcoholic ex-tracts from seventy-eight TCM,and then neutralized endo-toxin in vitro by selecting hypso-bonding TCM that re-moved the tannins.RESULTS: Twelve aqueous extracts and six alcoholic extracts from seventy-eight TCM had hypso-bonding with Lipid A (more than 200 response unit),and twelve aqueous extracts could bind specially endotoxin afterremoved tannins.CONCLUSION: Track of biosensortechnology is a quick,accurate and valid method in screening TCM.Aqueous extracts of twelve TCM can bind lipid A specially besides the tannins,and it is foundation to furthersegregate anti-endotoxin effective materials from twelve TCM in the future.

Key words: endotoxi, lipid A, biosensor, TCM, screen

CLC Number:

R285.5

CHEN Yi-guo, YAO Jie, ZHANG Xiang-wu, JIANG Dong-neng, GUO Yi-bin, WEI Li-zhao, CHENG Juan, WU Chong, ZHENG Jiang. Screening of anti-endotoxin traditional Chinese medicine by target of Lipid A[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2005, 10(12): 1349-1353.

References

1 Burchardi H,SchneiderH.Economic aspects of severe sepsis:a review of intensive care unit costs,cost of illness and cost effec-tiveness of therapy[J].Pharmacoeconomics,2004;22:793-813
2 Carrigan SD,Scott G,Tabrizian M.Toward resolving the chal-lenges of sepsis diagnosis[J].Clin Chem,2004;50:1301-14
3 Galanos C,Lu?deritz O.Synthetic and natural Escherichia coli free lipid A express identical endotoxic activities[J].EurJ Bio-chem,1985;148:1-5
4 Loppnow H,Duërrbaum I,Lipid A.The immunostimulatory prin-ciple of lipopolysaccharides[J].Endotoxin,1990;256:561-6
5 Masahito H,Yasuyuki A.Chemical structure and immunobiolog-ical activity of lipid A from Prevotella intermedia ATCC 25611lipopolysaccharide[J].FEBS Letters,2003;543:98-102
6 Cavaillon JM,HaeffnerCN.Polymyxin-B inhibition of LPS-in-duced interleukin-1 secretion by human monocytes is dependent upon the LPS origin[J].Mol Immunol,1986;23:965-9
7 SrimalS,Surolia N.Titration calorimetric studies to elucidate the specificity of the interactions of polymyxin B with lipopolysac-charides and lipid A[J].Biochem J,1996;315:679-86
8 Appelmelk B J,Su D.Polymyxin B-horseradish peroxidase con-jugates as tools in endotoxin research[J].Anal Biochem,1992;207:311-6
9 Yang MX,Chen JR.Self-assembled monolayerbased quartz crystal biosensors forthe detection of endotoxins[J].Analytical Letters,2002;35:1775-84
10 Jiang Z,Hong Z,Guo W,XiaoyunG,Gengfa L,Yongning L,et al.A synthetic peptide derived fro m bactericidal permeability-increasing protein neutralizes endotoxin in vitro and invivo[J].International Immunopharmacology,2004;4:527-37
11 Lv GF,Zheng J,ZhouH,Zheng YM,Wang LX,Wei G,et al.The screening and isolation of an effective anti-endotoxin mono-merfrom Radix Paeoniae Rubra using affinity biosensortechnol-ogy[J].International Immunopharmacology,2005;5;1007-17
12 Guo YB,Zheng J,ZhouH,Lv GF,Wang LX,Wei G,et al.A synthesized cationic tetradecapeptide from hornet venom kills bacteria and neutralizes lipopolysaccharide in vivo and in vitro[J].Biochemical Pharmacology,2005;70:209-19
13 刘云海,王迎春.中药抗内毒素活性初步筛选[J].中药材,2000;23:762

[1]	LIU Min, KONG Xiang, ZHANG Ye, GU Yifei, XIANG Xuemei, HE Qing, HUANG Kai. Analysis of reasons for screening failure of healthy subjects in clinical trials of orally inhaled drug products [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 758-766.
[2]	SUN Yuchen, LIU Yinhui, ZHANG Xian, YUAN Tong, JING Mengyao, ZAHNG Xinyu, YANG Jin. Exploration of screening criteria for healthy volunteers in human bioequivalence clinical trials [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(6): 714-720.
[3]	HUANG Tianpeng, HAO Jiale, YU Yan, WANG Yaoyao, FAN Xiaofang, GONG Yongsheng, MAO Sunzhong. Stimulation of Yes-associated protein activity attenuates lung injury repair induced by LPS in mice [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(3): 293-298.
[4]	LIU Xiaohong, LI Ling, QI Zhenhua, CHEN Binyao, ZHAO Huijia, HAO Zhuowen, YUE Jiang, YE Qifa，WU Jianguo. Farnesoid X receptor is an important target in lipid metabolism [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(8): 955-960.
[5]	ZHANG Xiping, ZHANG Xiang, YANG Hongjian, ZOU Dehong, QIAO Enqi, WANG Zhun, HE Xiangming, YU Xingfei, ZHANG Ying, TANG Binbin. Clinical trial of multiple compound Chinese medicine injections in the treatment of mice with chemotherapy-related leukopenia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(10): 1116-1125.
[6]	HE Yangbiao, YUAN Chunying, SHI Guojun. Effect of gexiazhuyu decoction on blood coagulable status and life quality of patients with liver cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(9): 1056-1061.
[7]	YANG Guoping, PEI Qi, PENG Jinfu. Development of traditional Chinese medicine based on material mapping [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(2): 121-123.
[8]	CHEN Wang, WEN Chun-jie, FU Li-juan. Preliminary study of the CYP2C19 genotype in the application of Chinese herbal medicine metabolism screening [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(9): 1016-1020.
[9]	ZHONG Cheng-liang, HU Si-yuan. Key technologies elements of clinical study of TCM new drugs on children's functional constipation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(9): 1025-1030.
[10]	YU Wen-ying, ZHANG Liang, CHEN Guo-shen, YE Jin-cui. Research progress in application of multi-component mixtures of enhancers in transdermal drug delivery [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(1): 103-109.
[11]	ZHU Jin-gang, XIE Dan-dan, CHENG Mao-liang. Clinical observation on integrated traditional Chinese and western medicine stroke unit therapy in treatment of 156 patients with cerebral stroke [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(5): 559-561.
[12]	WANG Hui, HU Si-yuan. Clinical research design technical points on child anorexia treated by new TCM drugs [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(10): 1191-1195.
[13]	YAO Xin-bao, TIAN Xiu-li, WEI Guo-yi. A better method to test bacterial endotoxin in lentinan for injection with the specific Tachypleus Amebocyte Lysate (B,C factor) [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(11): 1257-1259.
[14]	CHENG Juan, ZHANG Zhe. Combination of Chinese and western medicines on periodontal disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(8): 945-948.
[15]	YANG Dan-hong, YE Zai-yuan, HE Xu-jun, ZHANG Qin, ZHOU Wei-ming, XU Wen-juan, LV Huo-xiang. Improvement effect of salvianolate on small intestinal mucosal barrier in cirrhotic rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(7): 758-763.